Dihexa vs IDRA-21
A side-by-side research comparison of Dihexa and IDRA-21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa | IDRA-21 |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) | IDRA-21 (Benzothiadiazide AMPA PAM) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. |
| Molecular weight | 507.6 Da | 262.7 Da |
| Half-life | 6-12 hours | 8-12 hours (effects persist 48-72h) |
| Bioavailability | Moderate (oral/SubQ) | High (oral) |
| Typical dose | 10-20 mg (oral) or 2-5 mg (SubQ) | 10-30 mg |
| Frequency | Daily | 2-3x per week |
| Route | Oral or Subcutaneous | Oral |
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
Related comparisons
Research and educational reference only. Not medical advice.